Abstract
Alzheimers disease is a progressive, neurodegenerative disorder characterized by a devastating cognitive decline. The disease is identified pathologically by amyloid plaques composed of aggregated amyloid-β peptide, neurofibrillary tangles composed of aggregated, hyperphosphorylated tau protein and neuron loss. While the disease was first described in 1906, transgenic mouse models for the study of Alzheimers disease pathologies have only been available to scientists for fifteen years. Despite the generation of many different mouse models that develop amyloid plaques or neurofibrillary tangles, it has only been in recent years that mouse models demonstrating the two pathologies together have been made. Also, neuron loss has been difficult to achieve in many models. Most recently, several transgenic mouse lines have been generated that do demonstrate all three pathological characteristics of Alzheimers disease: amyloid plaques, neurofibrillary tangles and neuron loss. This review will focus on the advances made in our understanding of Alzheimers disease pathology using the transgenic mouse models. It will also discuss the limitations associated with studying some of these mice and how transgenic mouse models have contributed to the development of therapeutics for the treatment of Alzheimers disease.
Keywords: Alzheimer's disease, transgenic, amyloid, neurofibrillary tangles, neurodegeneration, amyloid precursor protein
CNS & Neurological Disorders - Drug Targets
Title: The Usefulness and Challenges of Transgenic Mouse Models in the Study of Alzheimers Disease
Volume: 9 Issue: 4
Author(s): Donna M. Wilcock
Affiliation:
Keywords: Alzheimer's disease, transgenic, amyloid, neurofibrillary tangles, neurodegeneration, amyloid precursor protein
Abstract: Alzheimers disease is a progressive, neurodegenerative disorder characterized by a devastating cognitive decline. The disease is identified pathologically by amyloid plaques composed of aggregated amyloid-β peptide, neurofibrillary tangles composed of aggregated, hyperphosphorylated tau protein and neuron loss. While the disease was first described in 1906, transgenic mouse models for the study of Alzheimers disease pathologies have only been available to scientists for fifteen years. Despite the generation of many different mouse models that develop amyloid plaques or neurofibrillary tangles, it has only been in recent years that mouse models demonstrating the two pathologies together have been made. Also, neuron loss has been difficult to achieve in many models. Most recently, several transgenic mouse lines have been generated that do demonstrate all three pathological characteristics of Alzheimers disease: amyloid plaques, neurofibrillary tangles and neuron loss. This review will focus on the advances made in our understanding of Alzheimers disease pathology using the transgenic mouse models. It will also discuss the limitations associated with studying some of these mice and how transgenic mouse models have contributed to the development of therapeutics for the treatment of Alzheimers disease.
Export Options
About this article
Cite this article as:
M. Wilcock Donna, The Usefulness and Challenges of Transgenic Mouse Models in the Study of Alzheimers Disease, CNS & Neurological Disorders - Drug Targets 2010; 9 (4) . https://dx.doi.org/10.2174/187152710791556168
DOI https://dx.doi.org/10.2174/187152710791556168 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adenosine and ATP Receptors in the Brain
Current Topics in Medicinal Chemistry Moderate Wine Consumption in the Prevention of Metabolic Syndrome and its Related Medical Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Clinical and Rehabilitative Management of Retinitis Pigmentosa:Up-to-Date
Current Genomics Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets [General Articles] Altered Protein Acetylation in Polyglutamine Diseases
Current Medicinal Chemistry Traumatic Brain Injury as a Risk Factor for Alzheimer’s Disease: Is Inflammatory Signaling a Key Player?
Current Alzheimer Research Cholinesterase Inhibitor 6-Chlorotacrine - In Vivo Toxicological Profile and Behavioural Effects
Current Alzheimer Research Meet Our Editorial Board Member
Current Neuropharmacology Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Current Neuropharmacology Gene Therapy in Peripheral Nerve Reconstruction Approaches
Current Gene Therapy Anti-inflammatory and Hypolipidemic Effect of Novel Conjugates with Trolox and Other Antioxidant Acids
Medicinal Chemistry Protein Aggregation in Neurodegenerative Diseases: Insights from Computational Analyses
Current Bioinformatics Physiological and Pathophysiological Functions of SIRT1
Mini-Reviews in Medicinal Chemistry RAGE: A Single Receptor for Several Ligands and Different Cellular Responses: The Case of Certain S100 Proteins
Current Molecular Medicine Preface: Developments in Understanding of Alzheimer Disease
Current Alzheimer Research Smart Biodegradable Nanoparticulate Materials: Poly-lactide-co-glycolide Functionalization with Selected Peptides
Current Nanoscience Modulation of Apoptosis in Acute Ischemic Stroke as Treatment Challenges
Current Immunology Reviews (Discontinued) Non-Viral Methods For Generating Integration-Free, Induced Pluripotent Stem Cells
Current Stem Cell Research & Therapy Nanobiotechnology-based Drug Delivery in Brain Targeting
Current Pharmaceutical Biotechnology Polypharmacology in a Single Drug: Multitarget Drugs
Current Medicinal Chemistry